Interventional Glaucoma

According to the company, latanoprost ophthalmic solution 0.005% successfully met the primary and all secondary endpoints, and it plans to file an NDA with the FDA in Q1 2023.

Shawn O'Neil of ViaLase shares updates on the company's femtosecond laser, image-guided, high-precision trabeculotomy (FLigHT) treatment.

The goal of World Sight Day, according to IAPB, is “to shine a light on blindness and vision impairment as a major, but solvable, public health issue."

Hear how ophthalmologists and optometrists in the United States are recognizing the importance of this year's awareness day.

Shawn O'Neil of ViaLase shares updates on the company's femtosecond laser, image-guided, high-precision trabeculotomy (FLigHT) treatment.

At AAO 2022, Dr Mitch Shultz provides discourse on iStent inject vs Hydrus contralateral eye evaluation data.

At AAO 2022, Mitch Shultz, MD, provides discourse on iStent inject vs Hydrus contralateral eye evaluation data.

A team of National Institutes of Health scientists have shed light on how genetic architecture determines gene expression, tissue-specific function, and disease phenotype in blinding diseases.

According to the Glaucoma Research Foundation, the collaborative research program will explore some of the common characteristics of glaucoma, Alzheimer’s.

Nanoscope Technologies LLC announced this week it has received Direct Phase II SBIR grant from National Institutes of Health for developing an innovative approach to autonomously regulate pressure for treatment of Glaucoma in a gene-agnostic manner.

This glaucoma session will offer a look at how to incorporate pearls into clinical practice.

Visiox Pharma has announced the submission of a New Drug Application to the FDA for lead product candidate, PDP-716.

The setting for this year's Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will provide the opportunity for clinical interaction between faculty and attendees along with the practicality of information.

Ophthalmologists can reduce IOP and medications with endocyclophotocoagulation while in the eye.

A combination of posters, podium presentations and instructional courses provided invaluable revelations to the ophthalmic community.

Gautam Kamthan, MD, presented data at AAO 2022 regarding robot-assisted micro interventional glaucoma surgery.

First-in-human biologic stent in ophthalmology is a conforming implant material, i.e., a soft, scleral wall compliant bio-tissue to structurally reinforce the cyclodialysis cleft opening.

Robot-assisted surgical precision offers less than 5-µm precision tremor stabilization, 1 to 10-mN force-sensing smart instrumentation and automated procedure-specific guidance and assistance with analytics.

In a poster presented at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago, Yu-Yen Chen, MD, PhD, noted that patients diagnosed with normal-tension glaucoma (NTG) have a significantly higher risk of developing Alzheimer’s disease compared with those without NTG.

13% of pediatric patients had new-onset strabismus after a tube shunt procedure; in contrast, 0% of adults had new-onset strabismus after tube shunt surgery (at 6 months or at last follow-up).

Following the lockdown due to COVID-19, investigators highlight the need to re-assess policies on patient follow-up and establish new approaches to provision of care for elderly patients.

The hour-long issue teaches the viewing ophthalmologist the technique and many modifications of intrascleral haptic fixation, an innovative approach when the capsule has been damage or is absent.

Genotyping and artificial intelligence are together starting to predict the progression of glaucoma in individual patients, sparing them from suboptimal treatments and adverse effects. Recent research efforts are exploring modifiable risk factors such as caffeine consumption.

The destination of Marco Island, Florida not only serves as an excellent backdrop for this year's Ophthalmology Times® EyeCon 2022 but also provides a unique opportunity for family members to see their ophthalmic loved ones in a professional light.

Mr Gokulan Ratnarajan recaps his 2022 ESCRS presentation: "A Real World Comparison Of iStent Combined With Phacoemulsification And Endocyclophotocoagulation (Ice2) With Preserflo And Xen-45 Implants In The UK; Short- And Long-Term Outcomes."